School of Pharmacy and Biomedical Sciences
Maudland Building, MB065
+44 (0) 1772 89 5805
Subject Areas: Chemistry
Tim is a lecturer in medicinal chemistry within the School of Pharmacy and Biomedical Sciences.
After graduating from the University of Nottingham in 2000 with an MSci (Hons) in Chemistry, Tim moved to the University of Liverpool to study for a Ph.D. under the guidance of Professor Stan Roberts, studying “The Synthesis and Biological Evaluation of Cyclopentenone Prostanoids”. Following on from this, Tim spent a brief spell with a contract chemical research company in Manchester (Ultrafine Ltd) before returning to academia and a postdoctoral position under the supervision of Professor Jonathan Clayden at the University of Manchester. Having completed his postdoctoral studies in 2006, Tim took up a Research Fellow position within the Centre of Excellence for Biocatalysis, Biotransformations and Biocatalytic Manufacture (CoEBio3) within the School of Chemistry, also at the University of Manchester. Once there, he spent the next two years establishing his research group and developing new synthetic methods to biologically important molecules and synthetic building blocks – a theme which continues in his role at UCLan, along with studying the biological and biophysical properties of the compounds made in the group.
Ph.D. Organic Chemistry, University of Liverpool, 2000-2003
MSci (Hons) Chemistry, University of Nottingham, 1996-2000
Membership of professional and learned bodies
Member of the Royal Society of Chemistry (MRSC), 2004-present
Chartered Chemist (CChem), 2009-present
Chartered Scientist (CSci), 2009-present
Fellow of the Higher Education Academy (FHEA), 2012-present
Our research group has interests in a number of areas including: synthetic organic chemistry - encompassing the development of rearrangement reactions, the use of enzymes in synthesis and the synthesis of heterocycles and foldamers, all of which are aimed at the synthesis of bioactive molecules and synthetically useful chemical building blocks; we are also interested in the biological activity of the molecules we make, and current interest lies in the anticancer and antimicrobial properties of a range of privileged structures and foldamers, and in particular their activity against a number of glioma cell lines and resistant bacteria.
Teaching activities and responsibilities
I currently teach a number of lectures on Foundation Organic Chemistry and Medicinal Chemistry in the following modules in the School:
Year 1 - Foundation Organic Chemistry - PJ1100
Years 2-4 - Medicinal Chemistry - PJ2100, BL4211, PJ4001, PJ4200, PJ4101
I am also the MPharm Admissions Tutor for the School
External Affiliations and Roles
Invited Member of the Editorial Board for Medicinal Chemistry & Drug Discovery (MCDD)
Imperial College London - APS Conference "Stimulating antimicrobial innovation" 22nd October 2015 –
Targeting the bacterial cell membrane with synthetic molecules that fold: exploiting the biological consequences of molecular origami and geometry - Invited lecture.
De Montfort University - 23rd September 2015 - Folded for success: exploiting the biological consequences of molecular origami - Invited lecture.
RSC North-West Organic Division Regional Symposium: Targeting the cell membrane with molecules that fold: exploiting the biological consequences of molecular origami. University of Liverpool, 20th May 2015.
Social MediaTim Snape website
Chiral 1,1-diaryl compounds as important pharmacophores: Dana M. Hamad Ameen and Timothy J. Snape,* Med. Chem. Commun., 2013, 4 (6), 893 - 907.
Synthetic oligoureas of metaphenylenediamine mimic host defence peptides in their antimicrobial behaviour: Sarah R. Dennison, David A. Phoenix, and Timothy J. Snape,* Bioorg. Med. Chem. Lett., 2013, 23, 9, 2518–2521.
Anionic antimicrobial and anticancer peptides from plants: Saurabh Prabhu, Sarah R. Dennison, Bob Lea, Timothy J. Snape, Iain D. Nicholl, Iza Radek and Frederick Harris, Crit. Rev. Plant Sci., 2013, 32, 303–320.
Preliminary biological evaluation and mechanism of action studies of selected 2-arylindoles against glioblastoma: Saurabh Prabhu, Zaheer Akbar, Frederick Harris, Katherine Karakoula, Robert Lea, Farzana Rowther, Tracy Warr and Timothy Snape,* Bioorg. Med. Chem., 2013, 21, 1918-1924.